Pancreatic Cancer Research

ResearcherNewcastle upon Tyne Hospitals NHS Foundation TrustNo recent work listed

Sivesh Kathir Kamarajah

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2748-0011; OpenAlex author ID A5087585718. Sources: OpenAlex.

Their work

Papers
14 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
74
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 7 papers · 2022: 1 paper · 2023: 1 paper

Papers 14

  1. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  2. Surgical Approach does not Affect Return to Intended Oncologic Therapy Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: A Propensity-Matched St… First author DOI 10.1245/s10434-022-12347-w↗
  3. Impact of SARS-CoV-2 pandemic on pancreatic cancer services and treatment pathways: United Kingdom experience. Co-author DOI 10.1016/j.hpb.2021.03.003↗
  4. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Da… Co-author DOI 10.1097/sla.0000000000003242↗
  5. Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic Surgery recommended pathways for resect… Co-author DOI 10.1111/ans.16643↗
  6. Neoadjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma is Associated with Lower Post-Pancreatectomy Readmission Rates: A Population-Based Cohort Study. Co-author DOI 10.1245/s10434-020-09470-x↗
  7. ASO Author Reflections: Is Neoadjuvant Chemotherapy Associated with Acceptable Short-Term Outcomes for Pancreatic Cancer? Co-author DOI 10.1245/s10434-020-09472-9↗
  8. Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population… Co-author DOI 10.1245/s10434-021-09823-0↗
  9. ASO Author Reflections: Postoperative Chemotherapy After Neoadjuvant Therapy and Pancreatectomy for Pancreatic Cancer: Balancing Patient Physiology and Disease… Co-author DOI 10.1245/s10434-021-09896-x↗
  10. A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarc… Co-author DOI 10.1016/j.hpb.2019.12.001↗
  11. Prehabilitation prior to surgery for pancreatic cancer: A systematic review. First author DOI 10.1016/j.pan.2020.07.411↗
  12. Body composition assessment and sarcopenia in patients with pancreatic cancer: a systematic review and meta-analysis. First author DOI 10.1016/j.hpb.2019.05.018↗
  13. Comments on: Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: Systematic review … Co-author DOI 10.1016/j.ijsu.2019.02.015↗
  14. Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiolo… Co-author DOI 10.1245/s10434-017-5810-x↗

Closest collaborators

The 25 strongest of 74 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fadi S. Dahdaleh · 5 shared papers, 2021–2022 · strength 1.12
  2. James Bundred · 4 shared papers, 2019–2020 · strength 0.64
  3. Samer A. Naffouje · 3 shared papers, 2021–2022 · strength 0.56
  4. George I. Salti · 3 shared papers, 2021–2022 · strength 0.56
  5. Steven Alan White · 3 shared papers, 2020–2023 · strength 0.43
  6. Keith John Roberts · 3 shared papers, 2019–2021 · strength 0.36
  7. Robert Peter Sutcliffe · 3 shared papers, 2021–2023 · strength 0.31
  8. Hari Nathan · 2 shared papers, 2017–2021 · strength 0.24
  9. Clifford S. Cho · 2 shared papers, 2017–2021 · strength 0.24
  10. Timothy L. Frankel · 2 shared papers, 2017–2021 · strength 0.24
  11. Jason W. Denbo · 1 shared paper, 2022 · strength 0.20
  12. Bilal A. Al-Sarireh · 2 shared papers, 2021–2023 · strength 0.19
  13. Theodore Steven Lawrence · 1 shared paper, 2021 · strength 0.15
  14. Filip Bednar · 1 shared paper, 2021 · strength 0.15
  15. Wasfi Alrawashdeh · 1 shared paper, 2020 · strength 0.15
  16. Derek Manas · 1 shared paper, 2020 · strength 0.15
  17. Sanjay Pandanaboyana · 1 shared paper, 2020 · strength 0.13
  18. Marit Kalisvaart · 1 shared paper, 2021 · strength 0.11
  19. Francesca Marcon · 1 shared paper, 2021 · strength 0.11
  20. Yuk Ting Ma · 1 shared paper, 2021 · strength 0.11
  21. Pankaj Punia · 1 shared paper, 2021 · strength 0.11
  22. Nikolaos A. Chatzizacharias · 1 shared paper, 2021 · strength 0.11
  23. Tess M. E. van Ramshorst · 1 shared paper, 2023 · strength 0.11
  24. Patrick Pessaux · 1 shared paper, 2023 · strength 0.11
  25. Jeffrey W. Chen · 1 shared paper, 2023 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.